SCHEMBL10047253

SCHEMBL10047253

Cc1ccccc1S(=O)(=O)N1[C@H](CC2CCCC2)[C@@H](SCCC(=O)OC(C)(C)C)[C@@H](C(=O)O)[C@@H]1c1ccc(Cl)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RABGGTB P53611 9/20 0.85
RABGGTA Q92696 9/20 0.85
FNTA P49354 1/20 0.48
PGGT1B P53609 1/20 0.48
PLA2G1B P04054 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
HCRTR1 O43613 2/20 0.34
CCR1 P32246 1/20 0.32
TP53 P04637 2/20 0.32
MDM2 Q00987 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TTR P02766 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
ALOX12 P18054 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073371 1.00 RABGGTB (0.85) RABGGTBRABGGTAFNTAPGGT1BPLA2G1B
SCHEMBL10047260 0.92 RABGGTB (1.00) RABGGTBRABGGTAFNTAPGGT1B
SCHEMBL10073357 0.92 RABGGTB (1.00) RABGGTBRABGGTAFNTAPGGT1B
SCHEMBL10047259 0.90 RABGGTB (1.00) RABGGTBRABGGTAFNTAPGGT1B
SCHEMBL10073361 0.90 RABGGTB (1.00) RABGGTBRABGGTAFNTAPGGT1B
SCHEMBL10072796 0.84 RABGGTB (0.60) RABGGTBRABGGTAFNTAPGGT1BPLA2G1B
SCHEMBL10047256 0.84 RABGGTB (0.60) RABGGTBRABGGTAFNTAPGGT1BPLA2G1B
SCHEMBL10073370 0.82 RABGGTB (1.00) RABGGTBRABGGTAHCRTR1TP53MDM2
SCHEMBL10047265 0.82 RABGGTB (1.00) RABGGTBRABGGTAHCRTR1TP53MDM2
SCHEMBL10047250 0.81 RABGGTB (0.83) RABGGTBRABGGTAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815935-B2 Inhibitors of protein prenyltransferases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-08-26 US disclosed
US-8815935-B2 Inhibitors of protein prenyltransferases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-08-26 US disclosed
US-20130102639-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-04-25 US disclosed
US-20130102639-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-04-25 US disclosed
US-8093274-B2 Inhibitors of protein prenyltransferases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-10 US disclosed
US-20110178138-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-07-21 US disclosed
US-20110178138-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-07-21 US disclosed
US-20100063114-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102639-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES RABGGTA, FNTA, RABGGTB RABGGTB 3/4885RABGGTA 1/4885FNTA 2/4885
US-20100063114-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES GGT1, FNTA, FNTB RABGGTB 17/4885RABGGTA 5/4885FNTA 2/4885
US-20110178138-A1 INHIBITORS OF PROTEIN PRENYLTRANSFERASES RABGGTA, FNTA, RABGGTB RABGGTB 3/4885RABGGTA 1/4885FNTA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.